2.08
-0.14(-6.31%)
Currency In USD
| Previous Close | 2.22 |
| Open | 2.13 |
| Day High | 2.17 |
| Day Low | 2.06 |
| 52-Week High | 6.88 |
| 52-Week Low | 1.61 |
| Volume | 5.16M |
| Average Volume | 7.47M |
| Market Cap | 287.64M |
| PE | -5.2 |
| EPS | -0.4 |
| Moving Average 50 Days | 3.62 |
| Moving Average 200 Days | 4.5 |
| Change | -0.14 |
Compass Therapeutics Provides Corporate Update
GlobeNewswire Inc.
Jan 06, 2026 1:00 PM GMT
The analyses of progression-free survival (PFS) and overall survival (OS) remain on track for late Q1 2026 in the ongoing Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer (B
Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Jan 05, 2026 9:30 PM GMT
BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced i
Compass Therapeutics Announces Key Leadership Appointments
GlobeNewswire Inc.
Jan 05, 2026 1:00 PM GMT
BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced t